Amlodipine Besylate
Product Images NDC 67296-0673

4 FDA label images from Redpharm Drug Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Amlodipine Besylate (NDC 67296-0673). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Copy Of Label (6729606721)

Copy Of Label (6729606721)
A prescription label for amlodipine besylate 10 mg tablets, containing 30 tablets. The label includes the NDC 67296-0673-1, lot number 100529 1, and expiration date 03/15. It states storage instructions at controlled room temperature (15-30°C). Manufacturer is Greenstone LLC, Peapack, NJ, with distribution by Redpharm Drug, Eden Prairie, MN. A barcode is present on the right side of the label.*
FDA Label Image

Chemical Structure (Amlodipine 01)

Chemical Structure (Amlodipine 01)
Chemical structure of amlodipine besylate showing the bicyclic ring system, ester groups, and aminoethyl side chain typical of this calcium channel blocker compound.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A Kaplan-Meier survival curve comparing composite clinical outcomes for amlodipine versus placebo over 24 months. The graph plots event rate on the y-axis against time in months on the x-axis, showing lower event rates for amlodipine compared to placebo. A text box displays statistical data including a p-value of 0.003, hazard ratio of 0.691, and 95% confidence interval of 0.54 to 0.88.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A forest plot chart titled 'Effects on Primary Endpoint of Amlodipine versus Placebo across Sub-Groups' showing hazard ratios with 95% confidence intervals. The chart compares outcomes by factors such as age, gender, baseline systolic blood pressure, baseline vessel disease, and PCI-stent status, with a vertical line at 1.0 indicating no difference between amlodipine and placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.